ReviewJournal of clinical medicine2022
The ENIGI (European Network for the Investigation of Gender Incongruence) Study: Overview of Acquired Endocrine Knowledge and Future Perspectives.
Review in Journal of clinical medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 35 citations in OpenAlex.
- Return of Research Results to Participants in Longitudinal Cohort Studies in Health Research: Findings From 24 Cohorts of the Amsterdam Cohort Hub.Health expectations : an international journal of public participation in health care and health policy · 2026Article
- Effects of Puberty Suppression and Sex Steroids on Weight, BMI, and Lipid Profiles in Danish Transgender Adolescents.The Journal of clinical endocrinology and metabolism · 2026Observational
- Cardiac function and coronary plaque development following masculinizing gender-affirming hormone therapy: A prospective cohort study.Andrology · 2025Article
- Interest in Fertility Preservation Among Adults Seen at a Gender Care Clinic.Journal of clinical medicine · 2025Article
- Gender-affirming hormone therapy: effects on cardiovascular risk and vascular function.Endocrine connections · 2025Article
- Transgender healthcare: metabolic outcomes and cardiovascular risk.Diabetologia · 2024Review
- Giant Intracranial Meningiomas Requiring Surgery in 2 Transgender Women Treated With Cyproterone Acetate.JCEM case reports · 2024Article
- Adipokine secretion and lipolysis following gender-affirming treatment in transgender individuals.Journal of endocrinological investigation · 2024Observational
- Understanding and Addressing Disinformation in Gender-Affirming Health Care Bans.Transgender health · 2024Article
- Chronotype changes after sex hormone use: A prospective cohort study in transgender users of gender-affirming hormones.Chronobiology international · 2024Article
- Article
- Cardiovascular Risk in Transgender People With Gender-Affirming Hormone Treatment.Circulation reports · 2023Review
- Effects of hormonal treatment on dermatological outcome in transgender people: a multicentric prospective study (ENIGI).Journal of endocrinological investigation · 2023Article
- Glucose Homeostasis, Diabetes Mellitus, and Gender-Affirming Treatment.Biomedicines · 2023Review
- Changes in Serum Testosterone and Adrenal Androgen Levels in Transgender Women With and Without Gonadectomy.The Journal of clinical endocrinology and metabolism · 2023Article
- Gender-affirming hormone therapy, mental health, and surgical considerations for aging transgender and gender diverse adults.Therapeutic advances in endocrinology and metabolism · 2023Review
- Integrating transgender care into mainstream medicine-an essay by Guy T'Sjoen and Joz Motmans.BMJ (Clinical research ed.) · 2022Article
- Endocrine Management of Adult Gender-Dysphoric/Gender-Incongruent Persons: A Clinical Practice Guideline from Endocrine Society of India.Indian journal of endocrinology and metabolismArticle
- IDEA Group Consensus Statement on Medical Management of Adult Gender Incongruent Individuals Seeking Gender Affirmation as Male.Indian journal of endocrinology and metabolismReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 5 institutions in 5 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Literature on the efficacy and safety of gender-affirming hormonal treatment (GAHT) in transgender people is limited. For this reason, in 2010 the European Network for the Investigation of Gender Incongruence (ENIGI) study was born. The aim of this review is to summarize evidence emerging from this prospective multicentric study and to identify future perspectives. GAHT was effective in inducing desired body changes in both trans AMAB and AFAB people (assigned male and female at birth, respectively). Evidence from the ENIGI study confirmed the overall safety of GAHT in the short/mid-term. In trans AMAB people, an increase in prolactin levels was demonstrated, whereas the most common side effects in trans AFAB people were acne development, erythrocytosis, and unfavorable changes in lipid profile. The main future perspectives should include the evaluation of the efficacy and safety of non-standardized hormonal treatment in non-binary trans people. Furthermore, long-term safety data on mortality rates, oncological risk, and cardiovascular, cerebrovascular and thromboembolic events are lacking. With this aim, we decided to extend the observation of the ENIGI study to 10 years in order to study all these aspects in depth and to answer these questions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.